Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) gapped up before the market opened on Thursday . The stock had previously closed at $120.85, but opened at $121.12. Alexion Pharmaceuticals shares last traded at $122.59, with a volume of 1,701,398 shares traded.

Several equities research analysts have commented on the company. Cowen and Company restated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, April 17th. Jefferies Group restated a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, May 29th. Piper Jaffray Cos. restated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, June 26th. Leerink Swann restated a “buy” rating and set a $216.00 price target (down from $217.00) on shares of Alexion Pharmaceuticals in a research note on Saturday, March 19th. Finally, BMO Capital Markets lowered Alexion Pharmaceuticals to a “buy” rating in a research note on Saturday, April 30th. Eight investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $193.07.

The stock has a market cap of $27.87 billion and a P/E ratio of 188.23. The company has a 50-day moving average price of $132.82 and a 200-day moving average price of $145.76.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.13 by $0.02. The company earned $701 million during the quarter, compared to analysts’ expectations of $710.98 million. During the same period last year, the firm posted $1.28 earnings per share. The company’s revenue was up 16.8% on a year-over-year basis. On average, analysts expect that Alexion Pharmaceuticals Inc. will post $5.06 earnings per share for the current year.

In related news, EVP John B. Moriarty sold 918 shares of Alexion Pharmaceuticals stock in a transaction on Monday, June 13th. The stock was sold at an average price of $135.72, for a total transaction of $124,590.96. Following the completion of the sale, the executive vice president now owns 51,360 shares of the company’s stock, valued at $6,970,579.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Martin Mackay sold 4,097 shares of Alexion Pharmaceuticals stock in a transaction on Monday, May 16th. The shares were sold at an average price of $139.20, for a total value of $570,302.40. Following the sale, the executive vice president now directly owns 42,706 shares of the company’s stock, valued at approximately $5,944,675.20. The disclosure for this sale can be found here.

A number of hedge funds have recently added to or reduced their stakes in ALXN. Dimensional Fund Advisors LP boosted its stake in Alexion Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 289,785 shares of the biopharmaceutical company’s stock worth $55,277,000 after buying an additional 6,189 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in Alexion Pharmaceuticals by 563.8% in the fourth quarter. BNP Paribas Arbitrage SA now owns 113,751 shares of the biopharmaceutical company’s stock worth $21,698,000 after buying an additional 96,615 shares during the last quarter. Jennison Associates LLC boosted its stake in Alexion Pharmaceuticals by 7.0% in the fourth quarter. Jennison Associates LLC now owns 7,346,024 shares of the biopharmaceutical company’s stock worth $1,401,254,000 after buying an additional 481,031 shares during the last quarter. I.G. Investment Management LTD. boosted its stake in Alexion Pharmaceuticals by 4.6% in the fourth quarter. I.G. Investment Management LTD. now owns 31,750 shares of the biopharmaceutical company’s stock worth $6,056,000 after buying an additional 1,410 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in Alexion Pharmaceuticals during the fourth quarter worth about $9,867,000.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.